Rough seas or smooth sailing? Navigating Collaboration Agreements
Rough seas or smooth sailing? Navigating Collaboration Agreements
Johnson & Johnson Innovation, JLABS , 329 Oyster Point Blvd , South San Francisco , CA
May 23, 2017 from 11:00 AM to 13:30 PM (PST)
$10 - $35
Rough seas or smooth sailing? - Navigating Collaboration Agreements
How do you develop a smart collaboration agreement? An effectively negotiated collaboration agreement builds and strengthens a productive scientific relationship by allowing parties to enter into a mutually beneficial relationship achieving the goals of both parties.
How do you make sure the agreement will fit your company objectives? An effective agreement should be clear, to both the research workers and managers of both parties, laying the groundwork for moving the results of research toward commercialization. It addresses the nature of the collaboration, the responsibilities and obligations of each party, the desired outcomes and next steps beyond the currently contemplated research.
At this event, we will walk through building components of a collaboration agreement, point out and discuss key terms and provisions that help make a quality agreement. The talk will provide real world examples and focus on the following topics:
- Intro to Collaboration Agreements / General provisions
- Statement of objectives/work
- Restrictions and opportunities created by agreements
- Real world examples from panel members
The panel members will share real life experiences through the R&D collaboration process and beyond. The workshop will examine key types of provisions and their effects on future development and funding opportunities. This "how to" workshop is geared towards life sciences startup
Guests will be provided supporting materials including:
- Key provisions guide
- Sample Collaboration agreements
This event is being hosted in conjunction with Deloitte. Deloitte is deeply committed to the life sciences industry. As an advisor to many leading health care and life sciences organizations, Deloitte has been instrumental in developing and implementing many strategies that helped shape the evolution and long-term success of this industry. At Deloitte, we serve from early-stage companies to the world's largest players. We know where you go and we can help you to realize your dreams. As with all our events, the "How to…Workshop" is informal and interactive so bring your questions with you!
Angela Rusakova | Lead Client Service and Audit Partner, Deloitte & Touche LLP read bio»
Yelda Kaya | Sr. Director Transactions, Johnson & Johnson Innovation read bio»
William J. Newell | CEO, Sutro Biopharma read bio»
Moderator: Lesley Stolz | Head of JLABS, CA, Johnson & Johnson Innovation, JLABS read bio»
9:00 AM | Registration, Breakfast, and Networking
9:30 AM | Components of a collaboration agreement
10:00 AM | Panel Discussion: Implications of Components
11:00 AM | Q&A
11:30 AM | Program Close
$25 | General Public
$15 | Student/Academic
JLABS @ SSF
329 Oyster Point Blvd - 3rd Floor
South San Francisco, California
Angela Rusakova | Lead Client Service and Audit Partner, Deloitte & Touche LLP
Angela has 20 years of experience serving both public and private companies with a focus on the life sciences industry. She works with companies in all stages of growth, from start-ups to SEC registrants. Her technical background includes complex accounting issues such as revenue recognition, equity, derivatives, stock-based compensation, and acquisitions. Angela has been involved in financing and M&A transactions, including initial public offerings, offerings in leveraged buyouts, and several secondary shares offerings. She has extensive international experience and is a certified public accountant in the United States and the United Kingdom. Angela also served as a CFO before returning to public accounting in 2003.
Yelda Kaya | Sr. Director Transactions, Johnson & Johnson Innovation
Yelda is the Senior Director of Transactions in Johnson & Johnson Innovation Center, California.
Leveraging a diverse career practicing emergency medicine, corporate law and business development, Yelda brings extensive experience to transactions delivering a unique breadth of deals across sectors with an established track record of successfully leading, structuring, negotiating and executing complex deals over the last 10 years.
Yelda joined the Johnson & Johnson family from GSK's worldwide business development group. She holds a MBBS, LLB and MBA from the University of Melbourne.
William J. Newell | CEO, Sutro Biopharma
Mr. Newell has over 24 years of senior management experience in the biotechnology industry. He joined Sutro Biopharma as CEO in January 2009. Previously, he served as the President of Aerovance, Inc., a venture-backed company developing clinical assets for respiratory diseases. Mr. Newell also was Chief Business Officer and Senior Vice President at publicly-traded QLT, Inc. and served in several senior management positions at public-traded Axys Pharmaceuticals, Inc. For the 16 years prior to joining Axys, Mr. Newell practiced corporate law in the San Francisco Bay Area. He is presently a member of the Board at Symic Bio. Mr. Newell is also a Board member on BIO's Emerging Companies Section and a member of the Board and of the Executive Committee of the California Life Sciences Association.
Lesley Stolz | Head of JLABS, CA, Johnson & Johnson Innovation, JLABS
Dr. Stolz has 20 years of business and corporate development experience working for companies that have been both technology platform and therapeutics focused. After two years negotiating partnering deals for Johnson & Johnson Innovation at the California Innovation Center, Lesley joined the JLABS team as Head of JLABS, CA, to participate in the mission of helping to catalyze new companies in the healthcare ecosystem. Prior to joining Johnson & Johnson Innovation, she held executive positions with BioTime, Inc., Sutro Biopharma, Inc., and Sunesis Pharmaceuticals where she was responsible for corporate strategy, fundraising and all aspects of partnering. Earlier in her career, she served as Senior Director, Business Development for Aerovance, Inc. and for GPC Biotech AG in Munich, Germany from 2002 to 2006. She also served in senior management positions at Cell Genesys, Discovery Partners International and Axys Pharmaceuticals. During her career she has work on over 45 collaboration agreements helping shape effective opportunities for early stage companies. Dr. Stolz received her Ph.D. in chemistry, and conducted postdoctoral research at Harvard Medical School's Department of Biochemistry and Molecular Pharmacology.